Table 1.
Characteristics of included reviews
study | trials/ participants |
age range |
SSRIs compared to placebo |
diagnoses considered |
outcome measures |
---|---|---|---|---|---|
Beasley 1991[7] |
17/ 2334 |
12-90 | fluoxetine | depression | suicidal acts suicidal ideation |
Khan 2000[26] |
14/ 6356 |
general population |
paroxetine; sertraline | not specified | suicide suicide attempt |
Fergusson 2005[8] |
189/ 18,413 |
general population |
not specified | depression | suicide suicide attempt |
Gunnell 2005[11] |
477/ 40,826 |
adults | fluoxetine; paroxetine; sertraline; fluvoxamine; citalopram; escitalopram |
not specified | suicide self-harm suicidal thoughts |
Dubicka 2006[24] |
unknown/ 2122 |
6-18 | fluoxetine; paroxetine; sertraline; citalopram |
MDD | suicide attempt self-harm preparatory acts suicidal thought |
Hammad 2006[25] |
16/ 2970 |
pediatric patients |
fluoxetine; paroxetine; sertraline; fluvoxamine; citalopram |
MDD,OCD,SAD | suicidality |
Apter 2006[20] |
5/ 1191 |
<18 | paroxetine | MDD,OCD,AD | suicidality |
Bridge 2007[18] |
27/ 3543 |
<19 | fluoxetine; paroxetine; sertraline; fluvoxamine; and escitalopram or citaloprama |
MDD,OCD,AD | suicide attempt preparatory act suicidal ideation |
Tauscher- Wisniewski 2007[19] |
53/ 11,448 |
18-65 | fluoxetine | Bulimia,OCD | suicidal behaviors suicidal ideation |
Beasley 2007[21] |
18/ 3751 |
>18 | fluoxetine | MDD | suicidal behaviors suicidal ideation |
Stone 2009[23] |
372/ 52,665 |
15-99 | fluoxetine; paroxetine; sertraline; fluvoxamine; citalopram; escitalopram |
not specified | suicidality |
Carpenter 2011[22] |
61/ 14,911 |
18-64 | paroxetine | depression, OCD,AD,PTSD |
suicidal behaviors suicidal ideation |
SSRI,selective serotonin reuptake inhibitor MDD,major depressive disorder
OCD,obsessive-compulsive disorder AD,anxiety disorder
SAD,social anxiety disorder (subtype of anxiety disorder) PTSD,posttraumatic stress disorder
a in this study results for escitalopram and citalopram were analyzed together,not separately